Bayer's Asian Regulatory Momentum Puts Pipeline Wins in the Spotlight While Legal Calendar Looms

Bayer secures Japan approval for Hyrnuo, China review for Aflibercept 8 mg; ESC data due Aug 28-31, glyphosate hearing Sept 14.

The past week has handed Bayer a pair of regulatory milestones in Asia that underscore how the German conglomerate is quietly broadening its pharmaceutical footprint. On Monday, Japanese authorities granted marketing approval for Hyrnuo, the company's oncology candidate targeting HER2-mutated non-small cell lung cancer. Days earlier, China's National Medical Products Administration accepted for review the company's application for Aflibercept 8 mg, an ophthalmology treatment for macular edema following retinal vein occlusion, backed by data from the Phase III QUASAR program.

The two approvals—one in oncology, one in ophthalmology—arrive in quick succession and give investors a tangible sense of how the company is advancing on multiple therapeutic fronts simultaneously. Hyrnuo addresses a relatively rare but aggressive form of lung cancer with few targeted options currently available, while the Chinese filing represents an early but necessary step toward a potential launch in the world's second-largest pharmaceutical market.

A Data-Rich Calendar Takes Shape

Investors won't have to wait long for the next piece of pipeline evidence. Bayer is slated to present fresh Phase III data from its cardiovascular, renal, and secondary prevention programs at the European Society of Cardiology congress in Munich, running from August 28 to 31. The presentation carries particular weight because it offers a read on the robustness of the clinical evidence in a therapeutic area the company has designated as strategically important.

That clinical update lands in a busy stretch of the corporate calendar. The rescheduled glyphosate settlement hearing—moved by a US district court in Missouri from August 19 to September 14—remains the key legal milestone, followed by third-quarter results due November 3.

The Legal Overhang Persists, But the Tone Has Shifted

The glyphosate litigation tied to the Monsanto legacy continues to shadow the equity story, yet recent court rulings have prompted a measurable reassessment of the risk profile. Market observers characterized a series of US judicial decisions on the matter last week as a significant reduction in downside risk for the company, even if the share price has yet to reflect that improved calculus.

That more constructive read has filtered through to the sell side. JP Morgan raised its price target on Bayer in mid-August from EUR 50.00 to EUR 61.00, maintaining an "Overweight" rating. The bank cited progress toward resolving US legal liabilities as the primary driver—a view that aligns with the rescheduled hearing and the broader shift in risk perception.

Agriculture Provides a Quiet Counterweight

While the courtroom drama dominates headlines, the Crop Science division continues to deliver steady operational results. The unit grew revenue 3.5 percent on a currency-adjusted basis in the second quarter of 2026, reaching EUR 4.91 billion. Demand for climate-resilient seeds drove the expansion—evidence that Bayer is holding its own in a structurally growing segment even as public attention gravitates toward litigation.

Where the Stock Stands

The shares are consolidating after a powerful run. Bayer traded at EUR 48.33 on Thursday, down 1.2 percent on the day, and roughly 2.2 percent above its 50-day moving average of EUR 47.75—a signal that the medium-term uptrend remains intact. The stock has gained 31 percent year-to-date and sits 70 percent higher over the past twelve months. It remains about 10 percent below the 52-week high of EUR 53.86 reached on July 3, while still trading a remarkable 89 percent above its November low—a measure of just how far the recovery has traveled.

For now, the investment case splits along two tracks. On one side sit confirmed regulatory advances in Asia, a near-term clinical data readout, and steady agricultural demand. On the other, the unresolved US litigation, whose next hearing date arrives only in mid-September. Between now and then, pipeline news flow is likely to carry the narrative.